Brussels – The European Commission, under the framework program for research and innovation “Horizon 2020” has assigned a fund of 5 million and 903,146 Euros to EURE-CART project (EURopean Endeavour for Chimeric Antigen Receptor Therapies), with MolMed’s coordination. EURE-CART will involve a consortium of nine partners from six European countries: in Italy, in addition to MolMed, San Raffaele and Bambino Gesù Hospitals and Superior health Institute and abroad Universitätsklinikum Würzburg – Klinikum Der Bayerische Julius-Maximilians -Universität (Germany), Fundacio Privada Institut de Recerca de L’hospital de la Santa Creu i Sant Pau (Spain), Fakultní Nemocnice s poliklinikou Foundation Ostrava (Czech Republic), Acromion GMBH (Germany), ARTTIC SAS (France). Eure-CART project’s main objective is conducting a multicentric clinical trial Phase I / IIa, first on human, to demonstrate the safety and efficacy of immunotherapy based on CART-CD44v6 lymphocytes in acute myeloid leukemia and multiple myeloma. (9Colonne)
